- Home
- NRC vs FHTX Comparison
NRC vs FHTX Comparison
Compare NRC & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRC
- FHTX
- Stock Information
- Founded
- NRC 1981
- FHTX 2015
- Country
- NRC United States
- FHTX United States
- Employees
- NRC N/A
- FHTX N/A
- Industry
- NRC Biotechnology: Commercial Physical & Biological Resarch
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NRC Health Care
- FHTX Health Care
- Exchange
- NRC Nasdaq
- FHTX Nasdaq
- Market Cap
- NRC 310.8M
- FHTX 278.1M
- IPO Year
- NRC N/A
- FHTX 2020
- Fundamental
- Price
- NRC $14.69
- FHTX $4.98
- Analyst Decision
- NRC
- FHTX Strong Buy
- Analyst Count
- NRC 0
- FHTX 8
- Target Price
- NRC N/A
- FHTX $12.63
- AVG Volume (30 Days)
- NRC 105.2K
- FHTX 118.7K
- Earning Date
- NRC 07-28-2025
- FHTX 08-05-2025
- Dividend Yield
- NRC 3.39%
- FHTX N/A
- EPS Growth
- NRC N/A
- FHTX N/A
- EPS
- NRC 0.77
- FHTX N/A
- Revenue
- NRC $140,314,000.00
- FHTX $24,173,000.00
- Revenue This Year
- NRC N/A
- FHTX $33.60
- Revenue Next Year
- NRC N/A
- FHTX $5.87
- P/E Ratio
- NRC $18.30
- FHTX N/A
- Revenue Growth
- NRC N/A
- FHTX N/A
- 52 Week Low
- NRC $9.76
- FHTX $2.95
- 52 Week High
- NRC $23.29
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NRC 52.98
- FHTX 41.62
- Support Level
- NRC $12.29
- FHTX $4.72
- Resistance Level
- NRC $14.43
- FHTX $5.24
- Average True Range (ATR)
- NRC 0.66
- FHTX 0.43
- MACD
- NRC 0.09
- FHTX -0.18
- Stochastic Oscillator
- NRC 97.56
- FHTX 12.77
About NRC National Research Corporation (Delaware)
National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.